Tadashi Matsumoto

President & CEO
ReqMed Company, Ltd.​
​​

Started my business career at Kyowa Hakko in 1981, as a member of the establishment of the molecular biology laboratory, and engaged in the development of basic technology and cloning of new genes. Experienced several ley positions related to new drug development at Kyowa Hakko followed by establishment of ReqMed Company, Ltd. in 1998 to invest in and foster entrepreneurship in domestic and international ventures, develop and market pharmaceuticals.
Before joining pharmaceutical industry, obtained Ph. D. in physical chemistry and molecular biology from the Graduate School of Pharmaceutical Sciences of Tokyo University.  Also, obtained MBA from the University of Tsukuba's evening graduate school for working adults. In the summer of 1997, he also completed the Executive Course at Stanford University Graduate School of Business. 

Speech title & Synopsis

Collaboration with Asian Partners 

ReqMed is drug development company.  We are developing Sodium Pentosan Polysulphate (NaPPS) for Knee-OA in P3 in Japan.  At this stage, we are interested in finding Taiwanese partners for distributing NaPPS in Taiwan, and Asian partners for manufacturing final products.  Beside NaPPS for kneeOA, the compound would be expected for other indications like as MPS or HTLV-1 associated myelopathy.  And we develop a drug for L-dopa induced dyskinesia.  Genetically we are closer in Asia rather than in European.  So, we might use mutual clinical study data inside Asia.  Therefore, we consider that a collaboration with Asian Partner could be very important.